Neuroderm stock surges, then plunges, after positive Parkinson's data

On Tuesday, Israel-based Neuroderm announced breakthrough results for its Parkinson's disease therapy.

By Nicole Gray • Jan. 1, 2015

2014's 9 biggest biopharma game-changers, according to industry experts

9 experts weigh in on the events and trends that mattered most in biopharma this past year.

By Nicole Gray • Dec. 19, 2014

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

CVS Health: Harvoni being prescribed at 2.5 times the rate of Sovaldi

Gilead's Harvoni is slated to become an even bigger blockbuster than Sovaldi.

By Sy Mukherjee • Dec. 19, 2014

AbbVie pins hopes for first major approval in 10 years on hep C drug

AbbVie is in desperate need of diversification, because it relies on just one drug, Humira, for 63% of its profits. Could its new hep C treatment be the answer?

By Nicole Gray • Dec. 19, 2014

Glaxo assures shareholders: Dividend payout secure despite sluggish sales

GlaxoSmithKline stands by its plan to distribute $1.25 per share to investors this year, despite the fact that share prices have fallen 14% on sluggish respiratory sales.

By Nicole Gray • Dec. 19, 2014

Amgen leukemia drug Blincyto's massive price tag: $178,000

Immunotherapy is the cutting edge of cancer treatment, but many of the newest, most effective drugs cost more than $100,000 per treatment.

By Nicole Gray • Dec. 19, 2014

The 14 drugs most likely to top global pharma sales in 2015 and 2020

Analysts predict many of the usual suspects will keep raking in the big bucks. But several newcomers are set to claw their way into the top 10 pack over the next six years.

By Sy Mukherjee • Dec. 18, 2014

Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign

Praluent (alirocumab) is being hailed as a "next-generation" cholesterol treatment with multi-billion dollar sales potential.

By Nicole Gray • Dec. 17, 2014

How Teva's CEO is preparing for a 2015 of patent expirations

While speaking to analysts in NY, Teva CEO Erez Vigodman outlined the company's growth strategy for next year.

By Nicole Gray • Dec. 16, 2014

The 11 biggest drug launches to watch in 2015

A new report predicts that candidates from Sanofi, BMS, Vertex, and Novartis will make up the biggest drug launches next year.

By Sy Mukherjee • Dec. 15, 2014

Philly transit authority launches class action against Gilead over Sovaldi price

This is the first major payer lawsuit against Gilead over Sovaldi's exorbitant price.

By Nicole Gray • Dec. 12, 2014

Teva 2015 revenue forecast $1 billion lower than expected

Foreign exchange moves and anticipated generic competition for Copaxone led the generics giant to downgrade earnings forecasts for 2015.

By Nicole Gray • Dec. 12, 2014

Brave new world of digital pharma marketing has privacy advocates balking

Pharma is fine-tuning its online advertising by working with third-party vendors, which link patients, prescription-drug records, and Web ads. 

By Nicole Gray • Dec. 11, 2014

'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden

When Pfizer wanted to hire new employees for a large production site near Stockholm, Sweden, the company added an element of mystery and values assessment to the process.

By Nicole Gray • Dec. 11, 2014

Teva launches generic of Pfizer's arthritis med Celebrex in the US

The first generic celecoxib capsules will now be available in the U.S. in 50-, 100-, 200-, and 400-mg strengths. 

By Nicole Gray • Dec. 11, 2014

ICYMI: AARP and GPhA on what to do about generic drug price hikes

The AARP's Leigh Purvis and Ralph Neas of the Generic Pharmaceutical Association agree on the need for more generics competition. But they look at the problem through distinct lenses.

By Nicole Gray • Dec. 10, 2014

Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory

Axim Biotechnologies currently has a non-psychotropic cannabinoid gum on the market as a nutraceutical, and is looking to move into the medical marijuana market.

By Nicole Gray • Dec. 5, 2014

ICYMI: Are low-cost generic drugs a thing of the past?

There's a growing sense that the covenant between companies that manufacture and market generic drugs and the consumers who rely on them is broken.  

By Nicole Gray • Dec. 3, 2014

Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg

About half of the jobs may be salvageable—but huge swaths of the R&D sector are slated for dismissal.

By Sy Mukherjee • Dec. 3, 2014

Why BMS is getting ready to slash up to 1,000 jobs in China

Amid corruption probes and market shifts in China, many pharma companies are retrenching. Sales reps will be feeling the brunt of BMS' layoffs.

By Nicole Gray • Dec. 2, 2014

Generic drug price hikes move Congress to consider consumer relief measures

Last year, prices for half of all generic drugs increased. In fact, they doubled for 10% of generics.

By Nicole Gray • Nov. 26, 2014

Takeda US CEO leaving after 22 years

As Takeda president and COO Christophe Weber seeks to overhaul management and offset losses from drugs going off patent, CEO Doug Cole has "decided to explore his options."

By Nicole Gray • Nov. 26, 2014

3 compounding pharmacies sue Express Scripts over blocked coverage

Express Scripts, the largest pharmacy benefits manager in the U.S., has been refusing to cover certain active ingredients used by compounding pharmacies.

By Nicole Gray • Nov. 25, 2014

Sacré bleu! Sovaldi to cost 38.8% less in France than in US

When it comes to procuring high-priced hep C meds for its citizens, France has savoir faire. A 12-week course of Gilead's Sovaldi will cost $51,373, the lowest price point in the EU.

By Nicole Gray • Nov. 21, 2014

The 14 best-performing CEOs in biotech and pharma

From return on shareholders' investments to market capitalization, these 14 execs are among the best in the business.

By Sy Mukherjee • Nov. 21, 2014